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Background and Purpose: Cilostazol, a phosphodiesterase 3’ inhibitor, is used in Asia-Pacific 
countries for stroke prevention, but rarely used elsewhere. In addition to weak antiplatelet 
effects, it stabilises endothelium, aids myelin repair and astrocyte-neuron energy transfer in 
laboratory models, effects that may be beneficial in preventing small vessel disease (SVD) 
progression.  
 
Methods: A systematic review and meta-analysis of unconfounded randomised controlled 
trials (RCTs) of cilostazol to prevent stroke, cognitive decline or radiological SVD lesion 
progression. Two reviewers searched for papers (01/01/19-16/07/19) and extracted data. We 
calculated Peto odds ratios (OR) and 95% confidence intervals (CI) for recurrent ischaemic, 
haemorrhagic stroke, death, adverse symptoms, with sensitivity analyses. The review is 
registered (CRD42018084742). 
 
Results: We included 20 RCTs (n=10505), 18 in ischaemic stroke (total n=10449) and two in 
cognitive impairment (n= 56); most were performed in Asia-Pacific countries.  Cilostazol 
decreased recurrent ischaemic stroke (17 trials, n=10225, OR=0.68, 95%CI=0.57 to 0.81, 
P<0.0001), haemorrhagic stroke (16 trials, n=9736, OR=0.43, 95%CI=0.29,0.64, P=0.0001), 
deaths (OR=0.64, 95%CI=0.49, 0.83, P<0.0009), systemic bleeding (n=8387, OR=0.73, 
95%CI=0.54, 0.99, P=0.04), but increased headache and palpitations, compared with 
placebo, aspirin or clopidogrel. Cilostazol reduced recurrent ischaemic stroke more when 
given long (>6months) vs short-term without increasing haemorrhage, and in trials with larger 
proportions (>40%) of lacunar stroke. Data were insufficient to assess effects on cognition, 
imaging, functional outcomes or tolerance. 
 
Conclusions: Cilostazol appears effective for long term secondary stroke prevention without 
increasing haemorrhage risk. However, most trials related to Asia-Pacific patients and more 
trials in Western countries should assess its effects on cognitive decline, functional outcome 





Cerebral small vessel disease (SVD) causes 25% of ischaemic stroke, most intracerebral 
haemorrhages, most vascular cognitive impairment and up to 45% of dementias, and other 
important ageing related co-morbidities.{Hachinski, 2019 #11743} There is no specific 
treatment to prevent SVD progression. In a review of SVDs mechanisms and therapeutic 
agents with relevant modes of action,1 we identified several licenced drugs including cilostazol, 
a phosphodiesterase 3′ inhibitor. In addition to mild antiplatelet effects,2 cilostazol has several 
actions targeting processes involved in SVD pathophysiology: endothelial dysfunction, myelin 
repair, neuroprotection and inflammation.1  
 
Cilostazol is used for stroke prevention in Asia-Pacific countries, but in Western countries it is 
used mostly for symptomatic peripheral vascular disease. Previous systematic reviews 
suggested that cilostazol prevented recurrent stroke.{Uchiyama, 2009 #8977}3,4 However, 
further trials have been published since the last review, no review has assessed cilostazol’s 
effects in relevant subgroups and few assessed adverse effects (bleeding, headaches, 
palpitations, etc) that could limit cilostazol tolerance.   
 
We performed a systematic review and meta-analysis to determine the effect of cilostazol on 
stroke recurrence, cognitive decline, radiological progression of SVD, intracerebral 
haemorrhage, death and adverse symptoms in patients with stroke or cognitive presentations 
of SVD.  
 
Methods 
We published the systematic review protocol on PROSPERO (registration No. 
CRD42018084742) in March 2018 and performed the review according to PRISMA 
standards.5  
 
We searched MEDLINE and EMBASE between 1990 and 16 July 2019 (see Supplement) for 
original articles reporting prospective randomised controlled trials of cilostazol in patients with 
stroke, small vessel disease, mild cognitive impairment or dementia.  We also searched 
clinical trial registries (www.isrctn.com; eudract.ema.europa.eu; www.strokecenter.org/), 
conference proceedings, bibliographies of review papers, previous systematic reviews and 
trials papers for relevant trials not identified in the search, and finally for secondary 
publications of included trials that might provide additional outcomes.  
 
We included randomised, controlled, unconfounded, trials in patients with stroke, mild 
cognitive impairment or dementia, or radiological features of SVD, who were randomised to 
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treatment with cilostazol. Control groups received placebo tablets, another antiplatelet or 
received no cilostazol (open label). We excluded trials only published as conference abstracts, 
where translation into English was not possible, or where the full text was not available.  
 
We included trials that reported any of the following: recurrent stroke (all, ischaemic, 
haemorrhagic), incident dementia, incident mild cognitive impairment, change in cognitive test 
scores including domain specific scores, intracranial haemorrhage, other major/fatal bleeding, 
other systemic bleeding complications, death, myocardial infarction, dependency in activities 
of daily living, symptoms related to cilostazol use (such as nausea, headache, palpitations), 
change in white matter hyperintensities (WMH), progression/development of lacunes, 
microbleeds, perivascular spaces, brain atrophy (assessed by volume or validated score). 
 
Two reviewers screened titles and abstracts of all identified articles (GB, CM), independently 
performed full text review of relevant papers, extracted data from included papers using 
standardised forms, and cross-checked their findings.  
 
We extracted data on trial setting (hospital, community, etc), number of participants, sex, 
inclusion illness, diagnosis method including cognitive testing, proportion with lacunar stroke, 
randomisation methods, time from onset of inclusion illness to randomisation, blinding, 
treatment dose, duration, control allocation, concomitant antiplatelet or other agents, methods 
of outcome assessment, and proportion of patients with outcomes as listed above by intention 
to treat populations. We assessed study quality using the CONSORT criteria.6   
 
Discrepancies between the two reviewers were resolved by discussion and a third reviewer 
(JMW) who cross-checked all data extraction.  
 
Meta-analysis: We entered data into RevMan5 (version 5.3) software package. For most 
analyses, we grouped trials according to: a) their time to randomisation (randomising in 
acute/subacute versus later after stroke); and b) use of other prescribed antiplatelet drug 
(none, cilostazol plus aspirin or clopidogrel versus aspirin or clopidogrel, cilostazol versus 
aspirin or clopidogrel) and meta-analysed each outcome. We meta-analysed symptoms by 
type. For death from all causes, we assumed no deaths in studies that did not report deaths. 
We used Peto odds ratio (OR) and 95% confidence intervals (CI) for the meta-analyses, a 




In exploratory sensitivity analyses, we ranked trials according to the proportion of patients with 
small vessel (lacunar) ischaemic stroke, dichotomised into <40% and ≥40% or unspecified. 
We also tested time from stroke to start of treatment, and other antiplatelet drugs used.  
 
We performed a meta-regression to test whether time to start treatment, proportion of patients 
with lacunar stroke, study duration or comparison antiplatelet agent influenced the effect of 
cilostazol, using R version 3.6.2 (https://cran.r-project.org/) meta package. 
 




We identified 572 articles but excluded 505 after abstract screening, and a further 43 after full 
text review (Figure 1). We included 20 unconfounded, original RCT’s, published in 24 papers, 
including 10505 participants (Table 1).  
 
Characteristics of Included Trials 
The 20 trials had a median sample size of 183, range 20-2672. Eighteen trials included 
patients with stroke (n=10449, Table 1) and two included patients with cognitive impairment 
or dementia of Alzheimer’s type and radiological evidence of SVD (n=56).8,9  
 
Of the 18 trials in patients with stroke, two only included patients with lacunar stroke (n= 
515),10, 11 three only included patients with intracranial artery stenosis (n=755),12-14 six only 
included patients with non-cardioembolic ischaemic stroke (n=5264),15-20 most trials excluded 
patients with cardioembolic stroke regardless of other inclusion criteria, and one trial included 
patients at high risk of intracerebral haemorrhage (n=1534).21 In 9/18 trials, the stroke was 
lacunar in ≥40% of participants (n=6943); in the other nine trials, <40% of patients had a 
lacunar ischaemic stroke or the subtype proportion was not specified (n=3262).  
 
The time to randomisation after diagnosis was <two weeks in eight (n=1940),11,13,14,18-20,22,23 
between two weeks and six months in five (n=2123),12,17,24-26 and six months or later in six 
trials (n=6406; including the one trial in cognitive decline/dementia)9,10,15,16,21,27 and was not 
stated in the other trial in cognitive decline.8 The duration of trial treatment was four weeks in 
three (n=344),18,19,27 10 weeks in one (n=57),10 four months in four (n=1236),11,20,22,23 six-to-
eight months in five (n=753; including both trials in cognitive decline/dementia)8,9,13,14,17, 12 
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months in one (n=68)26 and between 12 months and five years in six trials 
(n=8034).12,15,16,21,24,25    
 
Eight trials used placebo tablets, the rest were open label (Table 1). One trial in stroke and 
one in Alzheimer’s disease tested cilostazol versus control in the absence of any other 
antiplatelet drug; nine trials tested cilostazol plus aspirin or clopidogrel versus aspirin or 
clopidogrel; eight trials tested cilostazol versus aspirin or clopidogrel, and one trial tested 
cilostazol plus aspirin versus clopidogrel plus aspirin.  
 
Of the 18 trials that included patients with stroke, one27 did not record recurrent stroke 
outcomes, and one9 that included patients with cognitive impairment reported recurrent stroke, 
therefore 18 trials provided data on recurrent stroke (all, ischaemic, Supplement Table I). 
Sixteen trials reported recurrent haemorrhagic stroke, 18 reported death, three trials reported 
cognitive outcomes (two trials in patients with cognitive impairment, one trial in stroke),8-10 10 
trials reported major cardiac outcomes, seven assessed functional outcome (modified Rankin 
scale) but only five gave results (precluding meta-analysis of effects of cilostazol on 
dependency), and about half the trials reported adverse symptoms (headache, nausea, 
palpitations, systemic bleeding; Supplement Table II). Outcomes are summarised in Table 2. 
 
Recurrent Ischaemic Stroke:  
Eighteen trials (n=10225) reported recurrent ischaemic stroke (cilostazol 5127, control 5098). 
Cilostazol decreased recurrent ischaemic stroke (OR=0.68, 95%CI=0.57, 0.81, P<0.0001), 
Figure 2, without heterogeneity. Most benefit appeared in the nine trials testing cilostazol 
started more than two weeks after stroke (median 76 days; omitted in three trials) and given 
long term, where the ORs are all less than one regardless of comparator group or concomitant 
antiplatelet drug use (see sensitivity analyses below). In contrast, in the eight trials starting 
cilostazol within two weeks of stroke (median 9.6 days; omitted in four trials) and assessing 
outcome at one to four months, the ORs all overlapped one, although the acute/subacute trials 
were smaller than the later-implementation/longer duration trials. A similar effect was seen for 
any recurrent stroke (18 trials, n=10225, 5127 allocated cilostazol, 5098 allocated control) 
where cilostazol decreased the odds of any recurrent stroke (OR=0.61, 95%CI=0.523, 0.72, 
P<0.00001), without heterogeneity (Figure I). 
 
Haemorrhagic stroke:  
Sixteen trials (n=9736) reported recurrent haemorrhagic stroke (cilostazol 4885, control 4851). 
Overall, cilostazol reduced haemorrhagic stroke (OR=0.43, 95%CI=0.29, 0.64, P=0.0001), 
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Figure 3, without heterogeneity. The pattern of effect was similar to that seen in all stroke and 
ischaemic stroke although the reduced sample resulted in fewer individually significant results. 
 
Major Adverse Cardiovascular Events:  
Ten trials reported a composite outcome of MACE (cilostazol 4470, control 4478). Cilostazol 
decreased MACE (OR=0.66, 95%CI=0.57, 0.76, P<0.00001), without heterogeneity (Figure 
S2). Most benefit occurred in trials testing long-term cilostazol starting six months or more 
after stroke, where summary ORs are less than one regardless of whether cilostazol was 
compared with placebo or aspirin or of concomitant antiplatelet drug use.  
 
Death:  
Eighteen trials reported death from any cause (cilostazol 5123, control 5742). Overall, 
cilostazol decreased the odds of death (OR=0.64, 95%CI=0.49, 0.83, P=0.0009), Figure III, 
without heterogeneity. Most benefit occurred in trials randomising patients late after diagnosis 
whilst trials randomising soon after stroke were more equivocal.  
 
Cognition:  
Two trials provided meta-analysable results (cilostazol 29, control 27; Figure IV) but data were 
too sparse to draw conclusions. One trial (LACI-1) that could not be meta-analysed reported 
a mean difference (adjusted for baseline) in Trail Making Test A of -4.0 (-12.7 to 4.7, P=0.37).   
 
Radiological markers of SVD:  
Only three trials reported SVD imaging markers although each reported a different measure 
(silent infarcts, new ischaemic lesion, microbleeds). Overall 55/557 participants allocated 
cilostazol developed an imaging lesion compared to 48/581 allocated control (OR=1.22, 95% 
CI=0.81, 1.84, P=0.34). 
 
Adverse symptoms:  
The types of symptoms reported by each study varied (Supplement Table II). In general, 
patients allocated cilostazol had more headache, dizziness, palpitations, tachycardia and 
diarrhoea, but less constipation and non-stroke bleeding events (Table 2, Figure V). There 
was no heterogeneity for the above outcomes apart from systemic bleeding and palpitations 






Sensitivity analyses  
Lacunar vs non-lacunar stroke: In the eight trials with <40% or unstated proportion of patients 
with lacunar stroke (cilostazol 1639, control 1623), cilostazol did not reduce recurrent 
ischaemic stroke (OR=0.72, 95%CI=0.49, 1.07, P=0.10, without heterogeneity), Figure VIA. 
In the nine trials with 40% or more patients with lacunar stroke (cilostazol 3477, control 3466; 
of which, six trials, total n=4964, included 58% or more lacunar strokes), cilostazol reduced 
recurrent ischaemic stroke (OR=0.64, 95%CI=0.52, 0.79, P<0.0001, without heterogeneity). 
However, the effect of cilostazol on recurrent ischaemic stroke did not differ between the two 
subgroups (<40% or ≥40% with lacunar stroke), on formal testing (Chi2 for difference=0.27, 
P=0.60, I2=0%, P=0.60, without heterogeneity).  
 
Time from stroke to treatment: Patients allocated treatment within two weeks of stroke, and 
where treatment was generally continued for no more than four months, those allocated 
cilostazol had similar rates of recurrent ischaemic stroke (21/972) than those allocated control 
(19/968), OR=1.10, 95%CI=0.58, 2.05, P=0.78 without heterogeneity, Figure VIB. In patients 
starting treatment beyond two weeks after stroke (median), and where treatment was 
generally continued for six months to five years, those allocated to cilostazol had fewer 
recurrent ischaemic strokes (189/4155) than those allocated control (286/4130), OR=0.65, 
95%CI=0.54, 0.78. P<0.00001, without heterogeneity. However there was no evidence of a 
between group difference (acute versus late, Chi2 2.47, P=0.12, with moderate heterogeneity, 
I2=59.5%). 
 
Concomitant antiplatelet drugs: Trials which randomised between cilostazol and no cilostazol 
in the absence or presence of concomitant aspirin or clopidogrel showed similar benefit for 
cilostazol (no aspirin, OR=0.51, 95%CI=0.33, 0.79, P=0.003; all patients received aspirin or 
clopidogrel, OR=0.51, 95%CI=0.35, 0.74, P=0.0004), Figure VIC. However in trials where 
cilostazol was compared to aspirin or clopidogrel, including one trial randomising to cilostazol 
+ aspirin versus clopidogrel+aspirin,14 there was no definite benefit of cilostazol (OR=0.81, 
95%CI=0.65, 1.02, P=0.08). Across the three subgroups, there was evidence of between-
subgroup differences (Chi2 6.31, P=0.04), and moderate heterogeneity (I2=68.3%). Restricting 
the analysis to trials comparing cilostazol with one antiplatelet drug in the absence of another 
antiplatelet drug by excluding the TOSS2 trial, showed benefit of cilostazol over the other 
antiplatelet drug (OR=0.78, 95%CI=0.62 to 0.99, P=0.04, without heterogeneity) and removed 





Meta-regression: Meta-regression of time to treatment, duration of treatment, and proportion 
of lacunar strokes, adjusted for comparator antiplatelet agent, did not identify any significant 
subgroup effects on outcomes of recurrent ischaemic or haemorrhagic stroke.   
 
Sources of bias:  
The median trial quality was 23.5/37 (minimum 14, maximum 35), with methods sections 
attaining the lowest scores on average (Supplement Table III, Figure VII). 
Funnel plots on all stroke, and ischaemic stroke showed some skew suggesting reporting bias 





Cilostazol reduced recurrent stroke, recurrent ischaemic stroke, recurrent haemorrhagic 
stroke, death and MACE compared with control, in the presence or absence of aspirin, or 
when compared directly with aspirin (data were limited for comparison with clopidogrel). Most 
benefit occurred in trials that randomised patients at two or more weeks after stroke and 
administered cilostazol for at least six months or longer, without evidence of increased risk 
with long-term treatment. There were very few data on the effect of cilostazol on functional 
outcome, cognitive decline, or radiological markers of SVD. Adverse symptoms such as 
headache, palpitations, dizziness, and diarrhoea were clearly increased with cilostazol 
although, importantly, systemic bleeding events were reduced.  
 
The review limitations are related to the available data and include variation between trials in 
antiplatelet drug use, times to randomisation after stroke, durations of treatment, not reporting 
dependency outcomes, and lack of information on stroke subtypes. Included studies varied 
greatly in sample size and some studies had no events in either group for certain outcomes. 
Antiplatelet therapy has changed since some studies were completed. Guidelines now advise 
dual antiplatelets short term after TIA or minor ischaemic stroke, followed by clopidogrel longer 
term. Only one study compared cilostazol to clopidogrel and both groups also received 
aspirin.14 Only two trials recruited patients with cognitive presentations and only one trial in 
stroke assessed cognition. The median trial quality was moderate (23.5/37). Thus, despite the 
total available data from trials of cilostazol totalling over 10,000 patients, the conclusions have 
limitations. There were also strengths of the review, including prospective protocol registration, 
assessment of methodological quality, double assessment of papers and data extraction, and 




Cilostazol may have more benefit on several outcomes where participants were randomised 
later after stroke. Although arbitrary, the trials naturally dichotomised into those randomising 
within two weeks of stroke and those randomising at more than two weeks after stroke, of 
which about a third randomised between two weeks and six months and two thirds randomised 
after six months. Trials randomising more than six months after stroke had long durations of 
treatment and follow-up. Thus, the apparent benefit of cilostazol in trials randomising late 
rather than early may reflect the paucity of acute trials, shorter duration of treatment, higher 
proportion of lacunar strokes, or that cilostazol is less effective in preventing early recurrent 
stroke. Similar results have been seen with another phosphodiesterase inhibitor dipyridamole 
(PDE5 inhibitor) with mild-antiplatelet and pro-endothelial effects1 which reduced stroke 
recurrence whilst increasing headache, mostly in Western populations. The risk of stroke 
recurrence varies by stroke subtype, atherothromboembolic stroke recurrence risk being 
highest immediately after TIA/minor stroke, then declining, whereas lacunar stroke has lower 
risk of early recurrence but the rate remains elevated in the longer term.  
 
Cilostazol’s apparent greater benefit late after stroke could reflect several possible 
mechanisms. Weaker antiplatelet effects2 and hence inferior stroke prevention compared to 
aspirin or clopidogrel early after TIA/stroke (when stronger antiplatelet activity may be more 
beneficial) is supported by the neutral effect of cilostazol on ischaemic stroke recurrence 
compared to aspirin or clopidogrel (Figure VIC). Increasing benefit of cilostazol late after stroke 
was also demonstrated in CASISP, which found no difference in recurrent stroke between 
cilostazol and aspirin within six months of stroke, but increasing benefit of cilostazol versus 
aspirin thereafter.25 The increased benefit of cilostazol later after stroke may reflect that its 
mechanisms of action are more relevant to lacunar stroke where recurrence occurs late, 
supported by increased benefit in trials including more patients with lacunar stroke (Figure 
VIA). Potential benefits for lacunar stroke include endothelial stabilisation, improved myelin 
repair and better astrocyte-to-neuronal energy supply,1,10 all of which may take some time to 
accrue. The lower cerebral and systemic haemorrhage risks would also confer benefit over 
other antiplatelet drugs which typically have higher bleeding risk the longer they are given, a 
reason for early stopping of the SPS3 Trial (dual versus single antiplatelet drugs) for lacunar 
stroke28, and seen in the present meta-analysis even in the presence of other antiplatelet 
drugs. The PICASSO trial suggests that the benefits of cilostazol may extend to reducing 
recurrent stroke and systemic bleeding even in patients at high risk of intracerebral 
haemorrhage.21   
 
More data are needed to overcome the limitations of the current data, to determine the effect 
of cilostazol on functional and cognitive outcomes after stroke, and on delaying cognitive 
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decline. If the effects of cilostazol seen in laboratory models translate to people (myelin repair, 
improved neuronal energy supply and endothelial stabilisation) and help to prevent 
progression of brain injury, then cilostazol might also prevent physical decline seen in SVD. 
Future studies should compare cilostazol to modern antiplatelet regimes, stratify patients by 
stroke or cognitive impairment, provide more data on cognitive, imaging and functional 
outcomes, and on tolerability and compliance. Several ongoing studies address these issues. 
LACI-2 (ISRCTN 14911850) is assessing cilostazol long-term after lacunar ischaemic stroke 
in the UK including one year cognitive and brain MRI follow up (target n=400). The COMCID 
trial (Asia-Pacific) is assessing cilostazol’s effects on cognitive function, incident dementia and 
hippocampal volumes (NCT02491268). Other trials are assessing short-term effects of 
cilostazol on cerebrovascular reactivity (e.g. Oxford Haemodynamic Adaptation to Reduce 
Pulsatility Trial (OxHARP), NCT03855332, target n=76).  
 
Cilostazol shows promise for ischaemic stroke prevention, with lower risk of haemorrhagic 
complications, particularly long term. Its place in stroke therapy may be in chronic secondary 
prevention rather than the acute phase. However most data are from Asia Pacific countries 
where stroke aetiologies and other factors may differ from other world regions, hence the need 
for more data. Despite its encouraging safety profile (lower bleeding risk and death), cilostazol 
causes several symptoms (headache, palpitations, diarrhoea, nausea) which may limit 
tolerance, requiring more data to guide future routine use. It is licenced in Europe and the 
Americas for treatment of symptomatic peripheral vascular disease and stroke prevention 
where other antiplatelet agents have failed or are not tolerated. However more evidence is 
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Table 1: Characteristics of Included Studies 
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NS=not stated; UK=unknown; SVD=small vessel disease; ICH=intracerebral haemorrhage; LA=large artery; CE=cardioembolic; Cil=cilostazol; cont=control; ICA=internal 


















All stroke 18 10,225 242/5127 384/5098 0.61 (0.52, 0.72) <0.00001 33.5 0.18 
Ischaemic stroke 18 10,225 210/5127 305/5098 0.68 (0.57, 0.81) <0.00001 44.5 0.11 
Haemorrhagic stroke 16 9736 30/4885 72/4851 0.43 (0.29, 0.64) <0.0001 0 0.55 
MACE 10 8948 320/4470 470/4478 0.66 (0.57, 0.76) <0.00001 2.5 0.39 
Death, all cause 18 10,865 93/5123 144/5742 0.64 (0.49, 0.83) 0.0009 18.0 0.30 
Cognition 2 56 80 72 0.03 (-0.29, 0.35) 0.84 0.0 0 
Headache 14 9582 743/4804 413/4779 2.00 (1.76, 2.28) <0.00001 69 0.0001 
Dizziness 9 6837 349/3419 292/3418 1.22 (1.04, 1.44) 0.02 15 0.31 
Palpitations 10 9,147 281/4566 124/4581 3.14 (2.57, 3.84) <0.00001 54 0.02 
Tachycardia 5 5,396 145/2698 33/2698 3.74 (2.77, 5.06) <0.00001 43 0.15 
Diarrhoea 5 4,064 303/2434 126/2403 2.21 (1.78, 2.74) <0.00001 41 0.13 
Constipation 3 4,664 189/2334 268/2330 0.68 (0.56, 0.82) 0.0001 0 0.72 
Nausea 4 3,095 76/1548 53/1547 1.47 (1.02, 2.11) 0.04 0 0.88 
Systemic bleeding 12 8,387 79/4211 102/4176 0.73 (0.54, 0.99) 0.04 69 0.001 
Sensitivity analysis: effect on ischaemic stroke by sub-group 
Ischaemic stroke sub-type:a 
                       <40% lacunar stroke 
8 3262 68/1639 101/1623 0.72 (0.49,1.07) 0.10 14 0.32 
                       ≥40% lacunar stroke 9 6943 142/3477 222/3466 0.64 (0.52, 0.79) <0.0001 0 0.54 
                                     Test for subgroup difference Chi2=0.27, P=0.60, I2=0 
Time to treatment:a 
         <2 weeks of stroke (9.6 days)b 
8 1940 21/972 19/968 1.1 (0.58 2.05) 0.78 0 0.81 
         ≥2 weeks of stroke (76 days)b  10 8285 189/4155 286/4130 0.65 (0.54, 0.78) <0.0001 0 0.52 
                                    Test for subgroup difference Chi2= 2.47, P=0.12, I2=59.5 
Additional antiplatelet drugs: 
  Cil vs no Cil, no antiplatelet 
1 1067 30/533 57/534 0.51 (0.33, 0.79) 0.003 n/a n/a 
  Cil+Asp or Clop vs Asp or Clop 8 3044 40/1526 78/1518 0.51 (0.35, 0.74) 0.0004 0 0.88 
  Cil vs Asp or Clop 9 6114 140/3068 170/3046 0.81 (0.65, 1.02) 0.08 0 0.68 
                                    Test for subgroup difference Chi2=6.31, P=0.04, I2=68.3 
n/N=number of events/total number allocated to that group; OR=odds ratio; SMD= standardised mean difference; a Comparison is any cilostazol versus no cilostazol; b median 




Figure 1. PRISMA flow chart of study identification 
Figure 2. Effect of cilostazol on ischaemic stroke 
Figure 3. Effect of cilostazol on haemorrhagic stroke 
